Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Dow Jones pokes ahead after IBM's quantum injection, Nvidia earnings
11:44am, Thursday, 21'st May 2026
3:40pm: Proactive news headlines Tiziana Life Sciences Ltd (NASDAQ:TLSA) completed patient enrollment in its Phase 2a clinical trial evaluating intranasal...
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
11:00am, Thursday, 21'st May 2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
07:44am, Thursday, 21'st May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in...
Tiziana Life Sciences price target boosted on foralumab update
03:17pm, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy” rating, following updated clinical data fo
MongoDB price target lifted by Bank of America ahead of earnings on execution confidence, Atlas momentum
11:35am, Tuesday, 19'th May 2026
MongoDB Inc (NASDAQ:MDB) saw Bank of America raise its price target on the database software company ahead of its upcoming first quarter earnings report,...
Tiziana Life Sciences price target boosted on foralumab update
11:12am, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy”...
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
09:44am, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued to be well tolerated over extended treatment in patient
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
07:00am, Tuesday, 19'th May 2026
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
05:42am, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued to be well...
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial
09:08am, Thursday, 14'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported PET imaging results from two patients in a Phase 2 Multiple System Atrophy trial showing up to 35% and 24% reductions in brain inflammation markers fol
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
07:00am, Thursday, 14'th May 2026
BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD
S&P and Nasdaq close at record highs on ceasefire optimism and tech strength
12:22pm, Thursday, 16'th Apr 2026
4:20pm: Tech powers gains Stocks finished higher on Thursday, with both the S&P 500 and Nasdaq notching fresh record closes as investors continued to lean...
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
09:00am, Thursday, 16'th Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain inflammation and improve cognitive function l
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company's lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. Da
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
06:48am, Thursday, 16'th Apr 2026
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly...
